128 related articles for article (PubMed ID: 23821256)
1. A homogeneous time-resolved fluorescence assay to identify inhibitors of HIV-1 fusion.
Smeulders L; Bunkens L; Vereycken I; Van Acker K; Holemans P; Gustin E; Van Loock M; Dams G
Methods Mol Biol; 2013; 1030():11-7. PubMed ID: 23821256
[TBL] [Abstract][Full Text] [Related]
2. A time-resolved fluorescence assay to identify small-molecule inhibitors of HIV-1 fusion.
Dams G; Van Acker K; Gustin E; Vereycken I; Bunkens L; Holemans P; Smeulders L; Clayton R; Ohagen A; Hertogs K
J Biomol Screen; 2007 Sep; 12(6):865-74. PubMed ID: 17644771
[TBL] [Abstract][Full Text] [Related]
3. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
[TBL] [Abstract][Full Text] [Related]
4. A novel enzyme-linked immunosorbent assay for screening HIV-1 fusion inhibitors targeting HIV-1 Gp41 core structure.
Pang W; Wang RR; Gao YD; Yang LM; Sun Y; Huang JF; Tien P; Zheng YT
J Biomol Screen; 2011 Feb; 16(2):221-9. PubMed ID: 21297108
[TBL] [Abstract][Full Text] [Related]
5. Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion.
Melikyan GB; Egelhofer M; von Laer D
J Virol; 2006 Apr; 80(7):3249-58. PubMed ID: 16537592
[TBL] [Abstract][Full Text] [Related]
6. A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1.
Cai L; Gochin M
Antimicrob Agents Chemother; 2007 Jul; 51(7):2388-95. PubMed ID: 17452484
[TBL] [Abstract][Full Text] [Related]
7. Rapid and automated fluorescence-linked immunosorbent assay for high-throughput screening of HIV-1 fusion inhibitors targeting gp41.
Liu S; Boyer-Chatenet L; Lu H; Jiang S
J Biomol Screen; 2003 Dec; 8(6):685-93. PubMed ID: 14711394
[TBL] [Abstract][Full Text] [Related]
8. Addition of artificial salt bridge by Ile646Lys mutation in gp41 coiled-coil domain regulates 6-helical bundle formation.
Zhao L; Hu ZW; Tong P; Chen YX; Zhao YF; Li YM
Bioorg Med Chem Lett; 2013 May; 23(9):2727-32. PubMed ID: 23522564
[TBL] [Abstract][Full Text] [Related]
9. Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.
Bai Y; Xue H; Wang K; Cai L; Qiu J; Bi S; Lai L; Cheng M; Liu S; Liu K
Amino Acids; 2013 Feb; 44(2):701-13. PubMed ID: 22961335
[TBL] [Abstract][Full Text] [Related]
10. A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment.
Zhao L; Tong P; Chen YX; Hu ZW; Wang K; Zhang YN; Zhao DS; Cai LF; Liu KL; Zhao YF; Li YM
Org Biomol Chem; 2012 Aug; 10(32):6512-20. PubMed ID: 22760295
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 gp41: mediator of fusion and target for inhibition.
Weiss CD
AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
[TBL] [Abstract][Full Text] [Related]
12. The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance.
Chong H; Yao X; Qiu Z; Sun J; Qiao Y; Zhang M; Wang M; Cui S; He Y
J Antimicrob Chemother; 2014 Oct; 69(10):2759-69. PubMed ID: 24908047
[TBL] [Abstract][Full Text] [Related]
13. Synergistic inhibition of HIV-1 envelope-mediated membrane fusion by inhibitors targeting the N and C-terminal heptad repeats of gp41.
Gustchina E; Louis JM; Bewley CA; Clore GM
J Mol Biol; 2006 Dec; 364(3):283-9. PubMed ID: 17010381
[TBL] [Abstract][Full Text] [Related]
14. Development of a FRET assay for monitoring of HIV gp41 core disruption.
Xu Y; Hixon MS; Dawson PE; Janda KD
J Org Chem; 2007 Aug; 72(18):6700-7. PubMed ID: 17685571
[TBL] [Abstract][Full Text] [Related]
15. A mammalian two-hybrid system-based assay for small-molecular HIV fusion inhibitors targeting gp41.
Shui X; Lu X; Gao Y; Liu C; Ren F; Jiang Q; Zhang H; Zhao B; Zheng Z
Antiviral Res; 2011 Apr; 90(1):54-63. PubMed ID: 21352856
[TBL] [Abstract][Full Text] [Related]
16. Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation.
Vaillant A; Juteau JM; Lu H; Liu S; Lackman-Smith C; Ptak R; Jiang S
Antimicrob Agents Chemother; 2006 Apr; 50(4):1393-401. PubMed ID: 16569857
[TBL] [Abstract][Full Text] [Related]
17. Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation.
Miyauchi K; Kozlov MM; Melikyan GB
PLoS Pathog; 2009 Sep; 5(9):e1000585. PubMed ID: 19763181
[TBL] [Abstract][Full Text] [Related]
18. Six-helix bundle completion in the distal C-terminal heptad repeat region of gp41 is required for efficient human immunodeficiency virus type 1 infection.
Liu D; Wang H; Yamamoto M; Song J; Zhang R; Du Q; Kawaguchi Y; Inoue JI; Matsuda Z
Retrovirology; 2018 Apr; 15(1):27. PubMed ID: 29609648
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
Pan C; Liu S; Jiang S
J Formos Med Assoc; 2010 Feb; 109(2):94-105. PubMed ID: 20206833
[TBL] [Abstract][Full Text] [Related]
20. High-throughput screening method of inhibitors that block the interaction between 2 helical regions of HIV-1 gp41.
Jin BS; Lee WK; Ahn K; Lee MK; Yu YG
J Biomol Screen; 2005 Feb; 10(1):13-9. PubMed ID: 15695339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]